LUCENTIS
Total Payments
$1.1M
Transactions
113
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $5,090 | 3 | 0 |
| 2022 | $38,150 | 7 | 0 |
| 2021 | $32,163 | 8 | 0 |
| 2020 | $51,063 | 12 | 0 |
| 2019 | $130,315 | 16 | 1 |
| 2018 | $374,643 | 27 | 0 |
| 2017 | $473,591 | 40 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 109 | 100.0% |
| Food and Beverage | $278.09 | 4 | 0.0% |
Payments by Type
Research
$1.1M
109 transactions
General
$278.09
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RAINBOW STUDY A RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAPY FOR THE TREATMENT OF INFANTS BORN PREMATURELY WITH RETINOPATHY OF PREMATURITY | Novartis Pharmaceuticals Corporation | $748,128 | 0 |
| LONG-TERM FOLLOW UP IN RETINOPATHY OF PREMATURITY | Novartis Pharmaceuticals Corporation | $347,619 | 0 |
| Long-term follow up in retinopathy of prematurity | NOVARTIS PHARMACEUTICALS CORPORATION | $5,090 | 0 |
| RAINBOW STUDY A RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAPY FOR THE TREATMENT OF INFANTS BORN PREMATURELY WITH RETINOPATHY OF PREMATURITY | NOVARTIS PHARMACEUTICALS CORPORATION | $3,900 | 0 |
Top Doctors Receiving Payments for LUCENTIS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $1.1M | 109 |
| , MD | Ophthalmology | Stanford, CA | $124.13 | 1 |
| Sarah Read | Ophthalmology | Miami, FL | $54.22 | 1 |
| , MD | Retina Specialist | Miami, FL | $54.22 | 1 |
| Mina Chung | — | Rochester, NY | $45.52 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 4
- Transactions 113
About LUCENTIS
LUCENTIS is a drug associated with $1.1M in payments to 4 healthcare providers, recorded across 113 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2023. In 2023, $5,090 was paid across 3 transactions to 0 doctors.
The most common payment nature for LUCENTIS is "Unspecified" ($1.1M, 100.0% of total).
LUCENTIS is associated with 4 research studies, including "RAINBOW STUDY A RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAPY FOR THE TREATMENT OF INFANTS BORN PREMATURELY WITH RETINOPATHY OF PREMATURITY" ($748,128).